STOCK TITAN
  1. Home
  2. News
  3. WXXWY

Wuxi Biologics (Cayman) Inc. - WXXWY STOCK NEWS

Welcome to our dedicated news page for Wuxi Biologics (Cayman) (Ticker: WXXWY), a resource for investors and traders seeking the latest updates and insights on Wuxi Biologics (Cayman).

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wuxi Biologics (Cayman)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wuxi Biologics (Cayman)'s position in the market.

News
WuXi Biologics Named to CDP 'A List' for Water Security
Rhea-AI Summary
WuXi Biologics (2269.HK) has been recognized for its leadership in corporate transparency and performance on water security by CDP, securing a spot on its annual 'A List'. The company achieved an 'A' score in the Water Security category, placing it in the top 2% of over 23,000 evaluated companies. CEO Dr. Chris Chen highlighted sustainability as a key focus for the company's development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
-
News
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
Rhea-AI Summary
WuXi Biologics achieves Leadership level recognition in 2023 Climate Change Assessment by CDP with an 'A-' score, surpassing sector and regional averages. The company's proactive efforts in environmental management and transparency are highlighted, with a commitment to science-based carbon targets and emission-reduction roadmaps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
-
News
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
Rhea-AI Summary
WuXi Biologics (2269.HK) has been named a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics for the fourth consecutive year. The company ranks in the top 2% of nearly 1,000 companies in the pharmaceutical sector, showcasing strong ESG achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
none
News
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
Rhea-AI Summary
WuXi Biologics successfully completes the first manufacturing run at its drug substance facility MFG7 in Ireland, achieving the largest manufacturing scale to date by combining four 4,000-liter single-use bioreactors. The Cost of Goods (COGS) from this run is comparable to that of a 16,000-liter traditional stainless-steel bioreactor, reinforcing the comparable cost seen in over 100 runs at 12,000-liter scale single-use bioreactors. The Ireland site also received the Facility of the Year Award (FOYA) in the Operations category from ISPE in 2023 and attained ISO certifications for energy management, environmental management, and occupational health and safety management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
none
-
News
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
Rhea-AI Summary
WuXi Biologics launches WuXiaADCC PLUSTM, a high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) response, crucial for targeted antibody-based immunotherapy approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
News
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
Rhea-AI Summary
WuXi Biologics announced the granting of a patent for their WuXiBodyTM platform, a highly flexible engineering platform that enhances the characteristics of bispecifics. The platform has been granted patents in the U.S., Japan, and China and has been widely adopted globally since its launch in 2018. WuXiBodyTM can effectively break through the CMC barriers for the development of bispecific antibodies, shorten the process by 6-18 months, and significantly reduce manufacturing costs compared to other platforms. The platform enables almost any mAb sequence pairs to be assembled into bispecific constructs with low immunogenicity risk and a long in vivo half-life. As of December 31, 2023, there are 45 out-licensed WuXiBodyTM projects in various stages, with four in Phase Ⅰ clinical development. Two WuXiBodyTM projects are expected to have IND applications approved in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
News
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
Rhea-AI Summary
WuXi Biologics (2269. HK) signs research service agreement with BioNTech SE (Nasdaq: BNTX) to discover two undisclosed targets of preclinical investigational monoclonal antibodies. WuXi Biologics to receive $20 million upfront payment and additional payments for research, development, regulatory, and commercial milestones, as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
News
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
Rhea-AI Summary
WuXi Biologics (2269.HK) to expand commercial manufacturing capacity in the U.S., increasing total manufacturing capacity to 36,000 liters, creating 200 new jobs, and aiming for GMP release in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
News
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
Rhea-AI Summary
WuXi Biologics (2269.HK) has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, recognized as a sustainability leader by S&P Global. The company was ranked number one in its sector in the Corporate Sustainability Assessment (CSA). WuXi Biologics CEO, Dr. Chris Chen, expressed pride in the achievement, emphasizing the company's commitment to enhancing ESG capabilities and sustainable growth. WuXi Biologics has demonstrated its dedication to sustainability through various ESG achievements, including becoming a signatory to the United Nations Global Compact, receiving an AAA rating from MSCI ESG Ratings, and being awarded the EcoVadis Sustainability Rating's Platinum Medal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
News
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
Rhea-AI Summary
WuXi Biologics (2269.HK) has been awarded the EcoVadis Sustainability Rating's Platinum Medal, ranking in the top 1% of over 100,000 companies evaluated. The company has been recognized for outstanding performance across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, making it a trusted partner by global clients for its strong sustainability commitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
none
Stock WXXWY logo
Wuxi Biologics (Cayman) Inc.

OTC:WXXWY

WXXWY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

WXXWY Stock Data

7.39B
3.62B
0.01%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
China (Mainland)
No 108 Meiliang Road Mashan

About WXXWY

wuxi biologics provides an open-access, integrated technology platform for biologics drug development. we are the only true service platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. our single-source approach to biologics development saves our clients critical time and money. see below how our experience, capacities and quality make us a world leading (cdmo). experience wuxi biologics’ leadership team consists of industry experts with 15-20 years of experience in biological drug development in the u.s./eu. while at wuxi this team has contributed to 1 bla and 66 worldwide inds in just 3 years! expertise wuxi biologics has over 170+ returnees from large pharma and small biotechs in the u.s./eu. these scientists cover all facets of drug development from discovery to manufacture of final drug product. capacity and capabilities we have strong technical capabilities and an open-access